GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (OTCPK:CGNSF) » Definitions » EBIT

CGNSF (Cognetivity Neurosciences) EBIT : $-3.05 Mil (TTM As of Oct. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences EBIT?

Cognetivity Neurosciences's earnings before interest and taxes (EBIT) for the three months ended in Oct. 2023 was $-0.52 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Oct. 2023 was $-3.05 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cognetivity Neurosciences's annualized ROC % for the quarter that ended in Oct. 2023 was -36.54%. Cognetivity Neurosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2023 was -5,654.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cognetivity Neurosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2023 was -171.37%.


Cognetivity Neurosciences EBIT Historical Data

The historical data trend for Cognetivity Neurosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognetivity Neurosciences EBIT Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
EBIT
Get a 7-Day Free Trial -3.17 -1.99 -1.46 -10.35 -4.77

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.26 -1.23 -0.72 -0.58 -0.52

Competitive Comparison of Cognetivity Neurosciences's EBIT

For the Health Information Services subindustry, Cognetivity Neurosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognetivity Neurosciences's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's EV-to-EBIT falls into.



Cognetivity Neurosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cognetivity Neurosciences  (OTCPK:CGNSF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cognetivity Neurosciences's annualized ROC % for the quarter that ended in Oct. 2023 is calculated as:

ROC % (Q: Oct. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jul. 2023 ) + Invested Capital (Q: Oct. 2023 ))/ count )
=-2.604 * ( 1 - 0% )/( (6.819 + 7.434)/ 2 )
=-2.604/7.1265
=-36.54 %

where

Note: The Operating Income data used here is four times the quarterly (Oct. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Cognetivity Neurosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Oct. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jul. 2023  Q: Oct. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.064/( ( (0.039 + max(-9.234, 0)) + (0.034 + max(-10.23, 0)) )/ 2 )
=-2.064/( ( 0.039 + 0.034 )/ 2 )
=-2.064/0.0365
=-5,654.79 %

where Working Capital is:

Working Capital(Q: Jul. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.203 + 0 + 0.037) - (3.817 + 0.096 + 5.561)
=-9.234

Working Capital(Q: Oct. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.184 + 0 + 0.025) - (4.137 + 0.079 + 6.223)
=-10.23

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Oct. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cognetivity Neurosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Oct. 2023 )
=-3.047/1.778
=-171.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cognetivity Neurosciences EBIT Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognetivity Neurosciences Business Description

Traded in Other Exchanges
Address
800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Cognetivity Neurosciences Headlines

From GuruFocus

The Most Innovative Healthcare AI Developments of 2019

By ACCESSWIRE AccessWire 04-12-2019